The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 28, 2025
Filed:
May. 09, 2022
St. Jude Children's Research Hospital, Inc., Memphis, TN (US);
Marcus Fischer, Memphis, TN (US);
Fatemeh Keramatnia, Memphis, TN (US);
Kevin Mcgowan, Memphis, TN (US);
Jaeki Min, Memphis, TN (US);
Gisele A. Nishiguchi, Memphis, TN (US);
Jeanine Price, Memphis, TN (US);
Zoran Rankovic, Memphis, TN (US);
Sourav Das, Memphis, TN (US);
Charles G. Mullighan, Memphis, TN (US);
Yunchao Chang, Memphis, TN (US);
St. Jude Children's Research Hospital, Inc., Memphis, TN (US);
Abstract
In one aspect, the disclosure relates to substituted N-(2-(2,6-dioxopiperidinyl-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfo namide analogs that useful as modulators of cereblon (CRBN) activity, methods of making same, pharmaceutical compositions comprising same, and methods of treating various clinical conditions and disorders using same, e.g., a disorder of uncontrolled cellular proliferation, such as a cancer, which may be associated with cereblon protein dysfunction and/or a GSPT1 dysfunction. In various further aspects, the disclosed compounds can selectively modulate the degradation of GSPT1 protein, i.e., the disclosed compounds can act as GSPT1 degraders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.